Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 10.73
XON's Cash to Debt is ranked higher than
69% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. XON: 10.73 )
XON' s 10-Year Cash to Debt Range
Min: 10.73   Max: No Debt
Current: 10.73

Equity to Asset 0.67
XON's Equity to Asset is ranked higher than
73% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XON: 0.67 )
XON' s 10-Year Equity to Asset Range
Min: -2.12   Max: 0.8
Current: 0.67

-2.12
0.8
Z-Score: 7.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -143.24
XON's Operating margin (%) is ranked higher than
69% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. XON: -143.24 )
XON' s 10-Year Operating margin (%) Range
Min: -1008.77   Max: -244.2
Current: -143.24

-1008.77
-244.2
Net-margin (%) -235.21
XON's Net-margin (%) is ranked higher than
64% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. XON: -235.21 )
XON' s 10-Year Net-margin (%) Range
Min: -1043.69   Max: -164.06
Current: -235.21

-1043.69
-164.06
ROE (%) -29.83
XON's ROE (%) is ranked higher than
75% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. XON: -29.83 )
XON' s 10-Year ROE (%) Range
Min: -172.6   Max: -172.6
Current: -29.83

ROA (%) -22.30
XON's ROA (%) is ranked higher than
76% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. XON: -22.30 )
XON' s 10-Year ROA (%) Range
Min: -61.45   Max: -12.55
Current: -22.3

-61.45
-12.55
ROC (Joel Greenblatt) (%) -273.26
XON's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. XON: -273.26 )
XON' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -804.38   Max: -328.59
Current: -273.26

-804.38
-328.59
» XON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

XON Guru Trades in Q4 2013

Daniel Loeb 2,539,200 sh (+18.07%)
David Einhorn 2,209,228 sh (+1.49%)
RS Investment Management Sold Out
» More
Q1 2014

XON Guru Trades in Q1 2014

Daniel Loeb 3,000,000 sh (+18.15%)
David Einhorn 1,379,014 sh (-37.58%)
» More
Q2 2014

XON Guru Trades in Q2 2014

Jean-Marie Eveillard 661,564 sh (New)
Daniel Loeb 2,900,000 sh (-3.33%)
David Einhorn 375,000 sh (-72.81%)
» More
Q3 2014

XON Guru Trades in Q3 2014

Jean-Marie Eveillard 790,364 sh (+19.47%)
Daniel Loeb 2,900,000 sh (unchged)
David Einhorn 197,278 sh (-47.39%)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Einhorn 2014-09-30 Reduce -47.39%0.06%$17.86 - $26.59 $ 26.4924%197278
David Einhorn 2014-06-30 Reduce -72.81%0.39%$15.3 - $25.93 $ 26.4925%375000
Jean-Marie Eveillard 2014-06-30 New Buy0.04%$15.3 - $25.93 $ 26.4925%661564
David Einhorn 2014-03-31 Reduce -37.58%0.26%$22.5 - $36.82 $ 26.49-8%1379014
Daniel Loeb 2014-03-31 Add 18.15%0.18%$22.5 - $36.82 $ 26.49-8%3000000
Daniel Loeb 2013-12-31 Add 18.07%0.15%$17.65 - $25.5 $ 26.4926%2539200
Daniel Loeb 2013-09-30 New Buy1.2%$21.36 - $29.7 $ 26.4910%2150592
David Einhorn 2013-09-30 New Buy0.86%$21.36 - $29.7 $ 26.4910%2176868
T Boone Pickens 2013-09-30 New Buy0.47%$21.36 - $29.7 $ 26.4910%12000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Intrexon Corp

Daniel Loeb Comments on Intrexon Corporation - Jan 22, 2014

Equity Position: Intrexon Corporation (XON) ("Intrexon") We initially invested in Intrexon in 2011 in a private round and have continued to accumulate shares since its IPO in August 2013. We believe that Intrexon is an innovation leader in synthetic biology with a unique value proposition and proven leadership team. Most attractive to us is Intrexon's potential to transform multiple industries, including the health, food, and energy markets. 

Synthetic biology is an emerging discipline that applies engineering design principles to biologic systems. Broadly speaking, synthetic biology is about the design, modification, and regulation of gene programs to produce a desired outcome, such as the production of a novel antibody from a cell culture, the optimization of a specific gene trait in crops, or the amplification of wild type natural gas metabolism into an industrially feasible process. Over the past 15 years, Intrexon has developed deep expertise in synthetic biology as well as the adjacent fields of process optimization and data analysis to create a unique technology platform that enables the iterative, directed improvement of experimental design. 

To leverage its technology with collaborators, Intrexon has developed a unique business model that centers on Exclusive Channel Collaborations (ECCs) with partners. In exchange for providing access to their technology, Intrexon receives cost reimbursement (thus mitigating the need to raise additional external funds) and significant downstream economics. Because Intrexon's technology is scalable, its capaci ty to sign ECCs across multiple industries is limited only by the ambition of its partners. Indeed, to date, Intrexon has already signed over 15 ECCs including, notably, with Johnson & Johnson. Over the course of 2014 and beyond, we anticipate that Intrexon will sign multiple ECCs, creating a broad pipeline of projects and diversifying away from specific product risk.

Intrexon is led by Chairman and CEO Randal J. Kirk, one of the most successful healthcare leaders of all time. Kirk founded and led New River Pharmaceuticals until its acquisition by Shire, and led Clinical Data through the successful development and approval of the anti-depressant Viibryd before selling the company to Forest. 

While his track record of value creation speaks for itself, we especially like that Kirk has personally invested significantly in Intrexon's success through Third Security , which owns nearly 2/3 of Intrexon's shares outstanding. While Intrexon's business model may seem foreign to the healthcare industry, it reminds us of an undisputed technology leader: Qualcomm. Qualcomm out-licenses its CDMA technology and in return receives significant economics from its partners upon commercialization; the explosive growth of the global wireless communication market and its dominant position has driven Qualcomm to a $125 billion market cap. W hile we aren't saying that Intrexon will become a $125 billion company overnight, we will note the following two points: (1) the manipulation of DNA and gene sequences to produce beneficial outcomes is a well-established paradigm; (2) the global health, food, and energy markets dwarf the wireless communication market in size

 

 

From Daniel Loeb (Trades, Portfolio)'s Third Point fourth quarter 2013 commentary.

Check out Daniel Loeb latest stock trades

Top Ranked Articles about Intrexon Corp

5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers International Inc
According to GuruFocus list of 5-year lows, these Guru stocks have reached their 5-year lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers International Inc Read more...
Daniel Loeb Comments on Intrexon Corporation
Equity Position: Intrexon Corporation (XON) ("Intrexon") We initially invested in Intrexon in 2011 in a private round and have continued to accumulate shares since its IPO in August 2013. We believe that Intrexon is an innovation leader in synthetic biology with a unique value proposition and proven leadership team. Most attractive to us is Intrexon's potential to transform multiple industries, including the health, food, and energy markets.  Read more...

Ratios

vs
industry
vs
history
P/B 7.42
XON's P/B is ranked higher than
69% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. XON: 7.42 )
XON' s 10-Year P/B Range
Min: 3.71   Max: 9.74
Current: 7.42

3.71
9.74
P/S 55.19
XON's P/S is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. XON: 55.19 )
XON' s 10-Year P/S Range
Min: 6.12   Max: 69.97
Current: 55.19

6.12
69.97
EV-to-EBIT -37.29
XON's EV-to-EBIT is ranked higher than
53% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. XON: -37.29 )
XON' s 10-Year EV-to-EBIT Range
Min: -59.2   Max: -17.2
Current: -37.29

-59.2
-17.2
Current Ratio 4.62
XON's Current Ratio is ranked higher than
72% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. XON: 4.62 )
XON' s 10-Year Current Ratio Range
Min: 0.81   Max: 10.49
Current: 4.62

0.81
10.49
Quick Ratio 4.19
XON's Quick Ratio is ranked higher than
71% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. XON: 4.19 )
XON' s 10-Year Quick Ratio Range
Min: 0.81   Max: 10.49
Current: 4.19

0.81
10.49

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.94
XON's Price/Tangible Book is ranked higher than
68% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. XON: 13.94 )
XON' s 10-Year Price/Tangible Book Range
Min: 7.16   Max: 10.36
Current: 13.94

7.16
10.36
Price/Median PS Value 3.40
XON's Price/Median PS Value is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. XON: 3.40 )
XON' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 4.1
Current: 3.4

0.46
4.1
Earnings Yield (Greenblatt) -2.70
XON's Earnings Yield (Greenblatt) is ranked higher than
78% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. XON: -2.70 )
XON' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -2.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:I5X.Germany
Intrexon Corp was founded in 1998. The Company designs, builds and regulates gene programs and cellular systems to enable the development of new and improved products and processes across a variety of market sectors, including Health, Food, Energy and Environment.The Company operates in one segment. It uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company's revenues are derived in the United States of America and all of its assets are located in the United States of America. The Company is subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials and the health and safety of employees with respect to laboratory activities required for the development of products and technologies.
» More Articles for XON

Headlines

Articles On GuruFocus.com
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Our Partners
Tracking David Einhorn's Portfolio - Q3 2014 Update Nov 20 2014 - SEEKINGALPHA

More From Other Websites
INTREXON CORP Financials Nov 21 2014
Can the Rally in Intrexon (XON) Shares Continue? Nov 19 2014
Fibrocell Science Announces IND Allowed to Proceed to Develop New Treatment for Wounded Warrior... Nov 18 2014
Intrexon Announces Third Quarter 2014 Financial Results Nov 13 2014
INTREXON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 13 2014
Intrexon Announces Third Quarter 2014 Financial Results Nov 13 2014
Q3 2014 Intrexon Corp Earnings Release - After Market Close Nov 13 2014
ROI Land Investments Ltd. Closes $6,000,000 Equity Investment Nov 12 2014
ROI Land Investments Ltd. Closes $6,000,000 Equity Investment Nov 12 2014
Will Higher Expenses Hurt Intrexon (XON) Earnings in Q3? Nov 12 2014
Intrexon (XON) Looks Good: Stock Moves 11% Higher Nov 12 2014
Herb's seeing green: XON Nov 11 2014
Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301,... Nov 10 2014
Fibrocell Science Reports Third Quarter and Nine Month 2014 Financial and Operating Results Nov 07 2014
Study Demonstrates Automated Laser-based Cell Manipulation with Intrexon's Proprietary LEAP® System Nov 06 2014
Study Demonstrates Automated Laser-based Cell Manipulation with Intrexon's Proprietary LEAP® System Nov 06 2014
Intrexon to Announce Third Quarter 2014 Results and Host Conference Call on November 13th Nov 06 2014
Intrexon to Announce Third Quarter 2014 Results and Host Conference Call on November 13th Nov 06 2014
Fibrocell Science to Report Third Quarter 2014 Financial and Operating Results, and Host Conference... Oct 30 2014
SEC Warned Before About Early Release Weak Spot Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK